Rochester, NY – University of Rochester Medical Center (URMC) and the NCI Designated Wilmot Cancer Institute (Wilmot) seeks a visionary, inspirational leader with significant experience advancing early phase clinical trials to serve in the inaugural role of Director, Developmental Therapeutics (Director). This position offers the unique opportunity to expand a critical component of Wilmot – the program to support developmental therapeutics and early phase clinical trials – during a significant phase of its growth at one of the foremost academic institutions in the nation and one the nation's newest NCI Designated Cancer Centers. This exciting leadership position will be named and supported by the Linde Klein Professorship endowment.

Wilmot provides best-in-class cancer treatment and care to approximately three million people in New York State and conducts pivotal research with the goal of preventing and conquering cancer through innovations in science, patient care, education, and community outreach. Wilmot features an 87-bed flagship cancer center, 13 outpatient locations, and one of the state's largest blood and marrow transplant programs. Wilmot's 198 oncology physicians and 514 oncology nurses see more than 7,000 new cancer patients each year. In 2024, Wilmot researchers had $30.9 million in cancer funding, $25.8 million in peer reviewed funding and over $14 million in NCI funding.

URMC and UR Medicine (the clinical enterprise) form the centerpiece of the University's medical research, teaching, patient care, and community missions. URMC has an integrated administrative structure, budget, and strategic plan. As one of the nation's leading academic medical centers, URMC ranks among the top quarter of U.S. medical centers in federal research funding, has an overall budget of approximately $6 billion, and houses the flagship hospital, Strong Memorial Hospital. UR Medicine continues its growth and now includes seven additional community hospitals.

The Director will advance the Developmental Therapeutics Program for Wilmot, with a focus on creating a robust, clinical trial portfolio supporting Wilmot's patient population and furthering scientific and clinical discovery. They will serve as the subject-matter expert of developmental therapeutics and early phase oncology clinical trials to catalyze the operational expansion of the program including recruitment and retention of faculty and staff.

The successful Director will bring expertise in early phase oncology clinical trials, including strategic program assessment and process development to support efficient trial activation and expansion. The Director will be a collaborative, transparent, visionary leader of teams as well as a strong clinician and investigator. Candidates must possess an MD, MD/PhD, or equivalent from an accredited school of medicine, be board certified in an oncology specialty, and possess academic accomplishments to merit appointment at the rank of Associate Professor or higher at University of Rochester and be eligible for licensure in the State of New York.

For confidential nominations or expressions of interest, please contact Vinny Gossain, Andrew Bean, Ph.D., Katie Haddock, or Alana Penley through the office of Katie Haddock via khaddock@wittkieffer.com.

Copyright ©2025 Jobelephant.com Inc. All rights reserved.

Posted by the FREE value-added recruitment advertising agency

jeid-057757cceeb40149a71986ff6c4198a9